Cas:67614-68-0 N-(4-oxo-2,3-dihydro-1H-naphthalen-1-yl)acetamide manufacturer & supplier

Chemical Name:N-(4-oxo-2,3-dihydro-1H-naphthalen-1-yl)acetamide

CAS.NO:67614-68-0

Synonyms:N-(4-oxidanylidene-2,3-dihydro-1H-naphthalen-1-yl)ethanamide;N-(4-oxo-1,2,3,4-tetrahydro-1-naphthalenyl)acetamide;N-(1,2,3,4-tetrahydro-4-oxo-1-naphthyl)acetamide;Acetamide,N-(1,2,3,4-tetrahydro-4-oxo-1-naphthalenyl);N-(1,2,3,4-tetrahydro-4-oxo-1-naphtyl)acetamide

Molecular Formula:C₁₂H₁₃NO₂

Molecular Weight:203.23700

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:49.66000

Exact Mass:203.09500

LogP:2.68060

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like N-(4-oxidanylidene-2,3-dihydro-1H-naphthalen-1-yl)ethanamide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,N-(1,2,3,4-tetrahydro-4-oxo-1-naphtyl)acetamide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,N-(4-oxo-1,2,3,4-tetrahydro-1-naphthalenyl)acetamide Use and application,N-(1,2,3,4-tetrahydro-4-oxo-1-naphthyl)acetamide technical grade,usp/ep/jp grade.

Related News: After several years of R & D and improvement, the production process of commonly used generic drug bulk drugs is relatively mature, and the products of similar companies have high similarities. Therefore, the competitive advantage of bulk drug companies is mainly reflected in cost control. Companies with cost advantages can usually pass Competition to expand production capacity and further gain scale advantages, while having stable, high-quality upstream supply. N-(4-oxo-2,3-dihydro-1H-naphthalen-1-yl)acetamide manufacturer Further research on Oligomannate��s pharmacological mechanism and long-term safety and effectiveness is required, according to the NMPA statement. N-(4-oxo-2,3-dihydro-1H-naphthalen-1-yl)acetamide supplier Lilly did show much more conclusively that donanemab, which zeroes in on amyloid plaques, does reduce levels of the aggregates of misfolded proteins in the brain. This is what Biogen also showed with Aduhelm, and it turned out this week to be enough for a full FDA approval, hence the stock bump for Lilly. N-(4-oxo-2,3-dihydro-1H-naphthalen-1-yl)acetamide vendor In April 2019, Glenmark had received approval from the Drugs Controller General of India (DCGI) for Remogliflozin Etabonate after successfully completing Phase-3 clinical trials. N-(4-oxo-2,3-dihydro-1H-naphthalen-1-yl)acetamide factory Optimize the reaction and improve the production process to reduce the production cost. At the same time, strengthen the determination and analysis of impurities to improve product quality.